Skip to main content
. 2018 Nov 19;19(11):3645. doi: 10.3390/ijms19113645

Figure 7.

Figure 7

Interaction between local administration of Aripiprazole (APZ) and inhibitors Sxc and mGluR into the mPFC and MDTN on systemic MK801-evoked L-glutamate release in the mPFC. (A) indicates the effect of perfusion with APZ (20 μM) into the mPFC and MDTN (gray bar) on systemic MK801-evoked L-glutamate release in the mPFC. (B) indicates the effects of perfusion of LY341495 (1 μM), CPPG (100 μM), and CPG (1 mM) into the mPFC (gray bar) on the inhibitory effects of perfusion of 20 μM APZ into the mPFC on systemic MK801-evoked L-glutamate release in the mPFC, as compared with MK801 injection with APZ perfusion into the mPFC from (A). (C) indicates the effects of perfusion of LY341495 (1 μM), CPPG (100 μM), and CPG (1 mM) into the MDTN (gray bar) on the inhibitory effects of perfusion of 20 μM APZ into the MDTN on systemic MK801-evoked L-glutamate release in the mPFC, compared with MK801 injection with APZ perfusion into the MDTN from (A). In (A–C), ordinates: mean ± SD (n = 6) of the extracellular L-glutamate level in the mPFC (μM), abscissa: time after administration of MK801 (1 mg/kg, i.p.) (min). Black arrows indicate the intraperitoneal injection of MK801. (D) indicates the AUC value of the extracellular L-glutamate level in the mPFC (μM) after MK801 injection from 0 to 180 min of (A–C). ** p < 0.01; relative to Control (MK801 alone injection), ## p < 0.01: relative to MK801 injection with the perfusion of APZ into the mPFC or MDTN using LMM with Tukey’s post hoc test.